HR and breast cancer: When classified based on the subtype, the most represented was hormone receptor positive- HER2-negative (HR+/HER2-, n = 32, 62.7%), followed by HER2 positive (HER2+, n = 20, 39.2%) and triple negative BC (TNBC, n = 20, 39.2+%).